Literature DB >> 9270004

The classification of benign and malignant human prostate tissue by multivariate analysis of 1H magnetic resonance spectra.

P Hahn1, I C Smith, L Leboldus, C Littman, R L Somorjai, T Bezabeh.   

Abstract

1H magnetic resonance spectroscopy studies (360 MHz) were performed on specimens of benign (n = 66) and malignant (n = 21) human prostate tissue from 50 patients, and the spectral data were subjected to multivariate analysis, specifically linear-discriminant analysis. On the basis of histopathological assessments, an overall classification accuracy of 96.6% was achieved, with a sensitivity of 100% and a specificity of 95.5% in classifying benign prostatic hyperplasia from prostatic cancer. Resonances due to citrate, glutamate, and taurine were among the six spectral subregions identified by our algorithm as having diagnostic potential. Significantly higher levels of citrate were observed in glandular than in stromal benign prostatic hyperplasia (P < 0.05). This method shows excellent promise for the possibility of in vivo assessment of prostate tissue by magnetic resonance.

Entities:  

Mesh:

Year:  1997        PMID: 9270004

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Prediction of treatment response in head and neck cancer by magnetic resonance spectroscopy.

Authors:  Tedros Bezabeh; Olva Odlum; Richard Nason; Paul Kerr; Donna Sutherland; Rakesh Patel; Ian C P Smith
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

2.  Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo.

Authors:  M Albert Thomas; Thomas Lange; S Sendhil Velan; Rajakumar Nagarajan; Steve Raman; Ana Gomez; Daniel Margolis; Stephany Swart; Raymond R Raylman; Rolf F Schulte; Peter Boesiger
Journal:  MAGMA       Date:  2008-07-17       Impact factor: 2.310

Review 3.  Proton magnetic resonance spectroscopy of the central, transition and peripheral zones of the prostate: assignments and correlation with histopathology.

Authors:  Peter Swindle; Saadallah Ramadan; Peter Stanwell; Simon McCredie; Peter Russell; Carolyn Mountford
Journal:  MAGMA       Date:  2008-09-17       Impact factor: 2.310

4.  Recent Advances in Metabolic Profiling And Imaging of Prostate Cancer.

Authors:  Roopa Thapar; Mark A Titus
Journal:  Curr Metabolomics       Date:  2014-04

5.  Identification of Enterococcus, Streptococcus, and Staphylococcus by multivariate analysis of proton magnetic resonance spectroscopic data from plate cultures.

Authors:  R Bourne; U Himmelreich; A Sharma; C Mountford; T Sorrell
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

Review 6.  MR-visible lipids and the tumor microenvironment.

Authors:  E James Delikatny; Sanjeev Chawla; Daniel-Joseph Leung; Harish Poptani
Journal:  NMR Biomed       Date:  2011-04-27       Impact factor: 4.044

Review 7.  Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Authors:  Rachel S Kelly; Matthew G Vander Heiden; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-06       Impact factor: 4.254

Review 8.  High-resolution magic angle spinning 1H MRS in prostate cancer.

Authors:  Emily A Decelle; Leo L Cheng
Journal:  NMR Biomed       Date:  2013-03-26       Impact factor: 4.044

9.  Characterization of synovial tissue from arthritis patients: a proton magnetic resonance spectroscopic investigation.

Authors:  Carol A Hitchon; Hani S El-Gabalawy; Tedros Bezabeh
Journal:  Rheumatol Int       Date:  2009-01-28       Impact factor: 2.631

10.  High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsies.

Authors:  Jack J A van Asten; Vincent Cuijpers; Christina Hulsbergen-van de Kaa; Claudia Soede-Huijbregts; J Alfred Witjes; Albert Verhofstad; Arend Heerschap
Journal:  MAGMA       Date:  2008-11-25       Impact factor: 2.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.